These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26934663)

  • 1. Advances with polymer-free amphilimus-eluting stents.
    CARRIé D
    Minerva Cardioangiol; 2016 Jun; 64(3):339-53. PubMed ID: 26934663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the Cre8 Stent in Patients With Diabetes Mellitus.
    Carrié D
    Interv Cardiol; 2016 May; 11(1):47-50. PubMed ID: 29588705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
    Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
    Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer-free amphilimus-eluting stents in patients with diabetes mellitus.
    Romaguera R; Gómez-Lara J; Jacobi F; Gomez-Hospital JA; Cequier A
    Minerva Cardioangiol; 2014 Oct; 62(5):421-6. PubMed ID: 25295493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Musto C; Berti S; Dibié A; Maupas E; Antoniucci D; Schofer J
    Int J Cardiol; 2020 Feb; 301():50-55. PubMed ID: 31759686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Valgimigli M; Frati G; Kedhi E; Smits PC; Kaiser C; Genereux P; Galatius S; Kirtane AJ; Stone GW
    J Am Coll Cardiol; 2013 Aug; 62(6):496-504. PubMed ID: 23747778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cre8 amphilimus-eluting stent for the treatment of coronary artery disease: safety and efficacy profile.
    Pivato CA; Leone PP; Petriello G; Sanz-Sanchez J; Chiarito M; Stefanini GG
    Expert Rev Med Devices; 2020 Apr; 17(4):267-275. PubMed ID: 32151183
    [No Abstract]   [Full Text] [Related]  

  • 11. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
    Kimura T; Morimoto T; Natsuaki M; Shiomi H; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Takatsu Y; Nishikawa H; Yamamoto Y; Nakagawa Y; Hayashi Y; Iwabuchi M; Umeda H; Kawai K; Okada H; Kimura K; Simonton CA; Kozuma K;
    Circulation; 2012 Sep; 126(10):1225-36. PubMed ID: 22824435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in drug-eluting stents used in coronary artery disease.
    Synetos A; Toutouzas K; Karanasos A; Stathogiannis K; Triantafyllou G; Tsiamis E; Lerakis S; Stefanadis C
    Am J Med Sci; 2011 Nov; 342(5):402-8. PubMed ID: 21629039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
    Franzone A; Pilgrim T; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Räber L; Stortecky S; Wenaweser P; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Jun; 8(6):. PubMed ID: 26043895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.